checkAd
    Startseite > Aktien > AstraZeneca > Nachrichten
    AstraZeneca Aktie
    70,50
     
    EUR
    -0,70 %
    -0,50 EUR
    Letzter Kurs 11:02:56 Tradegate
    70,50
     
    EUR
    74 STK
    Geldkurs 18:56:05
    71,00
     
    EUR
    74 STK
    Briefkurs 18:56:05
    ISIN: US0463531089 · WKN: 886715 · SYM: ZEGA · Großbritannien

    Neueste Nachrichten

    CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
    02.05.24 · Business Wire (engl.) · AstraZeneca
    AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
    01.05.24 · Business Wire (engl.) · AstraZeneca
    ENHERTU (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
    29.04.24 · Business Wire (engl.) · AstraZeneca
    Q1 2024 results
    25.04.24 · Business Wire (engl.) · AstraZeneca
    IMFINZI (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
    16.04.24 · Business Wire (engl.) · AstraZeneca
    FASENRA approved for treatment of children aged 6 to 11 with severe asthma
    11.04.24 · Business Wire (engl.) · AstraZeneca
    ENHERTU Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
    06.04.24 · Business Wire (engl.) · AstraZeneca
    ENHERTU (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
    06.04.24 · Business Wire (engl.) · AstraZeneca
    IMFINZI (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
    05.04.24 · Business Wire (engl.) · AstraZeneca
    Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
    02.04.24 · Business Wire (engl.) · AstraZeneca
    VOYDEYA approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH
    01.04.24 · Business Wire (engl.) · AstraZeneca
    ULTOMIRIS (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
    25.03.24 · Business Wire (engl.) · AstraZeneca